mitochondrial biogenesis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-18. Anything still debated is marked as such rather than presented as settled.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
== Adverse effects == Genital infections seem to be the most common adverse effect of gliflozins. In clinical trials fungal infections, urinary tract infections and osmotic diuresis were higher in patients treated with gliflozins. In May 2015, the FDA issued a warning that gliflozins can increase risk of diabetic ketoacidosis (DKA, a serious condition in which the body produces high levels of blood acids called ketones). By reducing glucose blood circulation, gliflozins cause less stimulation of endogenous insulin secretion or lower dose of exogenous insulin that results in diabetic ketoacidosis. They can specifically cause euglycemic DKA (euDKA, DKA where the blood sugar is not elevated) because of the renal tubular absorption of ketone bodies. A particularly high risk period for ketoacidosis is the perioperative period. SGLT2 inhibitors may need to be discontinued before surgery, and are only recommended when someone is not unwell, is adequately hydrated, and can consume a regular diet. Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing. To lessen the risk of developing ketoacidosis after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. Canagliflozin, dapagliflozin, and empagliflozin should each be stopped at least three days before, and ertugliflozin should be stopped at least four days before scheduled surgery.
=== bai Operon Mechanism === Deconjugation: Before primary bile acids reach the bai operon and undergo 7ɑ-dehydroxylation they must be deconjugated from taurine or glycine by a bile salt hydrolase enzyme.> baiG (H+-dependent bile acid transporter): baiG encodes a bile acid transporter protein that allows bacteria to take up unconjugated bile acids for 7ɑ-dehydroxylation. baiB (bile-acid CoA ligase): The first step of primary bile acid 7ɑ-dehydroxylation is carried out by baiB, which facilitates the formation of a bile acid-CoA thioester intermediate. Simply put, this enzyme replaces a hydroxyl (-OH) group with a thioester-CoA (-SCoA) group. This reaction is ATP-dependent, also producing pyrophosphate and AMP as byproducts. Previous research suggests that BaiB acts upon bile acids with a free C-24 group. baiB shares amino acid homology with the Escherichia coli entE gene, coding for 2,3-dihydroxybenzoate-AMP ligase, and the Bifidobacterium brevis grsA and tycA genes, encoding Gramicidin S synthetase 1 and Tyrocidine synthetase 1 respectively. baiA2 (3-ɑ-hydroxysteroid dehydrogenase): The next enzyme to act after baiB, baiA2 catalyzes the oxidation of the C-3 hydroxyl group into a carbonyl group. This enzyme replaces the hydroxyl (-OH) group with a carbonyl (C=O) group. This enzyme is part of a short-chain dehydrogenase/reductase enzyme family that characteristically requires a NAD+/NADP+ cofactor for functionality. Research into the cofactor binding site of baiA2 has revealed that it specifically uses NAD+ due to its structure.
Typhoid epidemics also broke out in the resettlement camps, which were often isolated, located far from urban areas, and lacked health facilities, sanitation, and schools. The forced relocations of blacks to the Ciskei resulted in high population densities in the homeland, a situation that persists to the present day. On several occasions, the Ciskei government imposed collective punishment on communities that opposed its rule, and people fled the Bantustan back into South Africa proper, because of the harassment and denial of government services to dissenters. In common with other Bantustans, its independence was not recognised by the international community. Sebe once claimed that the State of Israel had granted official recognition to Ciskei, but the Israeli Foreign Ministry denied this.
== Nomenclature == In 1997, Jamie I. Fletcher and his research associates introduced new nomenclature for classifying Australian funnel web spider toxins. They suggested replacing the trivial name 'versutoxin' with delta-hexatoxin-Hv1 instead. The delta represents the main biological activity of the neurotoxin; inhibiting sodium channels. In more recent research, atracotoxins have been rebranded as hexatoxins, but the two are still used interchangeably along with the abbreviations HXTX and ACTX. Delta and Hv1 are still used to specify the neurotoxic peptide versutoxin.
Sources: en.wikipedia.org
Valve did not develop a non-VR version of Alyx as they were confident that it would only be possible in VR. They anticipated that fans would modify it to run without VR equipment. Though this bothered some on the team, Walker was not concerned, as he believed it would offer an inferior experience and demonstrate why they had chosen VR. In late 2018, Valve held a company-wide playtest of the entire game. The results convinced them that VR had been the right choice. The final weeks of development took place remotely due to the COVID-19 pandemic.
Aspirin: may increase valproate concentrations. May also interfere with valproate's metabolism. Benzodiazepines: may cause CNS depression and there are possible pharmacokinetic interactions. Carbapenem antibiotics: reduce valproate levels, potentially leading to seizures. Cimetidine: inhibits valproate's metabolism in the liver, leading to increased valproate concentrations. Erythromycin: inhibits valproate's metabolism in the liver, leading to increased valproate concentrations. Ethosuximide: valproate may increase ethosuximide concentrations and lead to toxicity. Felbamate: may increase plasma concentrations of valproate. Mefloquine: may increase valproate metabolism combined with the direct epileptogenic effects of mefloquine. Oral contraceptives: may reduce plasma concentrations of valproate. Primidone: may accelerate metabolism of valproate, leading to a decline of serum levels and potential breakthrough seizure. Rifampicin: increases the clearance of valproate, leading to decreased valproate concentrations. Warfarin: valproate may increase free warfarin concentration and prolong bleeding time. Zidovudine: valproate may increase zidovudine serum concentration and lead to toxicity.
==== Omicron variant ==== During the emergence of the Omicron variant of COVID-19 in December 2021 and January 2022, Ford's government announced in December 2021 new restrictions on indoor settings. After growing calls for third or booster doses of COVID-19 vaccines, the government allowed all Ontarians over 18 years of age to receive a third dose on December 20, 2021. On January 3, 2022, Ford announced that Ontario would be moving into modified Step 2 on January 5, closing indoor dining, gyms, movie theatres and schools.
Sources: en.wikipedia.org
This urge EPI to create a strategy to encompasses both vaccines and medicines to be able to sustain their components without the need of storage. The term 'cold chain' has now been replaced with 'supply chain'. The current system of vaccine cold chain still continues for delivering particular vaccines. WHO has made improvements by introducing the "controlled temperature chain" (CTC), which is an innovative approach allowing the vaccine to be taken out of the cold chain for a limited period of time, but CTC is still in the development process and will not be available for all vaccines for many years. Nowadays, engineers is still thinking of a way to eliminate refrigeration at +2 to +8C from the entire supply chain for all vaccines. With the initiatives of reducing temperature sensitivity of vaccines and regulation permits, it could eliminate the need for refrigeration in the supply chain. It will be suitable for an undeveloped country as less handling of vaccines needs to be done.
=== Violent depictions of mental illness === The negative stigma that surrounds mental illness has real-life consequences for those who experience these illnesses. Many studies, both in the form of experimental designs and surveys, have concluded that media exposure does affect the stigmatization of mental illness. Despite the media's common depictions of mentally ill characters being violent or engaging in criminal activities, it is much less common in the real world than the media makes it seem. Of the 40+ million people in the U.S. who are classified as experiencing mental illness, violence or criminality occurs only in 10-12% of mental illness cases. However, as film and television programs utilize this trope for dramatic storytelling, the public often falsely assumes that the real world mirrors the mass media depictions. Scholars began analyzing this trend in the 1950s, yet the issue persists into the 21st century. In the late 1950s, the concern regarding mass media portrayals of mental illness started becoming more prominent. At the time, television network censors were used to determine the level of viewing (adults only, family-friendly, or needed altered content) that was appropriate based on the film's content. George Gerbner, before he developed cultivation theory, studied the films that were censored and found that in 1951, only five films contained representations of mental illness. However, by 1957, the number rose to 170 films, demonstrating the growing concern over misrepresentations and their effects.
== Awards == In 2004 the ELGA CENTRA received an Industrial Product Design Award; in 2009 the PURELAB Ultra was the Readers Choice Laboratory Equipment winner: the ELGA PURELAB flex received the Instrument Business Outlook (IBO) Silver design award for Laboratory Equipment Industrial Design in 2009, the Aquatech China Innovation Gold Award in 2010 and the Industrial Product Design Gold Award, the Materials Innovation Gold Award, the dBA Design Effectiveness and the Red Dot Award in 2011; in 2011 the ELGA PURELAB Pulse also received the Scientists Choice Award.
Carbohydrate catabolism is the breakdown of carbohydrates into smaller units. Carbohydrates are usually taken into cells after they have been digested into monosaccharides such as glucose and fructose. Once inside, the major route of breakdown is glycolysis, in which glucose is converted into pyruvate. This process generates the energy-conveying molecule NADH from NAD+, and generates ATP from ADP for use in powering many processes within the cell. Pyruvate is an intermediate in several metabolic pathways, but the majority is converted to acetyl-CoA and fed into the citric acid cycle, which enables more ATP production by means of oxidative phosphorylation. This oxidation consumes molecular oxygen and releases water and the waste product carbon dioxide. When oxygen is lacking, or when pyruvate is temporarily produced faster than it can be consumed by the citric acid cycle (as in intense muscular exertion), pyruvate is converted to lactate by the enzyme lactate dehydrogenase, a process that also oxidizes NADH back to NAD+ for re-use in further glycolysis, allowing energy production to continue. The lactate is later converted back to pyruvate for ATP production where energy is needed, or back to glucose in the Cori cycle. An alternative route for glucose breakdown is the pentose phosphate pathway, which produces less energy but supports anabolism (biomolecule synthesis). This pathway reduces the coenzyme NADP+ to NADPH and produces pentose compounds such as ribose 5-phosphate for synthesis of many biomolecules such as nucleotides and aromatic amino acids.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.